氯氮平与癫痫发作风险:一级预防还是二级预防?

IF 1.3 Q4 NEUROSCIENCES Progress in Neurology and Psychiatry Pub Date : 2022-10-01 DOI:10.1002/pnp.768
D. Yadav
{"title":"氯氮平与癫痫发作风险:一级预防还是二级预防?","authors":"D. Yadav","doi":"10.1002/pnp.768","DOIUrl":null,"url":null,"abstract":"Clozapine is licensed for treatment‐resistant schizophrenia. Clozapine dosage is normally adjusted according to each patient's clinical response and the side‐effect profile, but caution is advocated when using clozapine, due to its association with potentially life‐threatening side‐effects. One such adverse reaction is the risk of seizures. There is much debate as to how to prevent clozapine‐induced seizures: some authors recommend primary and some, secondary prophylaxis with antiseizure drugs. This article highlights an interesting case study and explores various factors that must be considered before a decision is made to prescribe anticonvulsant medication.","PeriodicalId":43913,"journal":{"name":"Progress in Neurology and Psychiatry","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Clozapine and seizure risk: primary or secondary prophylaxis?\",\"authors\":\"D. Yadav\",\"doi\":\"10.1002/pnp.768\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Clozapine is licensed for treatment‐resistant schizophrenia. Clozapine dosage is normally adjusted according to each patient's clinical response and the side‐effect profile, but caution is advocated when using clozapine, due to its association with potentially life‐threatening side‐effects. One such adverse reaction is the risk of seizures. There is much debate as to how to prevent clozapine‐induced seizures: some authors recommend primary and some, secondary prophylaxis with antiseizure drugs. This article highlights an interesting case study and explores various factors that must be considered before a decision is made to prescribe anticonvulsant medication.\",\"PeriodicalId\":43913,\"journal\":{\"name\":\"Progress in Neurology and Psychiatry\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Neurology and Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pnp.768\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neurology and Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pnp.768","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 1

摘要

氯氮平被许可用于治疗难治性精神分裂症。氯氮平的剂量通常会根据每位患者的临床反应和副作用进行调整,但在使用氯氮平时应谨慎,因为氯氮平会产生潜在的危及生命的副作用。其中一种不良反应是癫痫发作的风险。关于如何预防氯氮平引起的癫痫发作,有很多争论:一些作者建议使用抗癫痫药物进行初级和次级预防。这篇文章强调了一个有趣的案例研究,并探讨了在决定开抗惊厥药物之前必须考虑的各种因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clozapine and seizure risk: primary or secondary prophylaxis?
Clozapine is licensed for treatment‐resistant schizophrenia. Clozapine dosage is normally adjusted according to each patient's clinical response and the side‐effect profile, but caution is advocated when using clozapine, due to its association with potentially life‐threatening side‐effects. One such adverse reaction is the risk of seizures. There is much debate as to how to prevent clozapine‐induced seizures: some authors recommend primary and some, secondary prophylaxis with antiseizure drugs. This article highlights an interesting case study and explores various factors that must be considered before a decision is made to prescribe anticonvulsant medication.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
8.30%
发文量
44
期刊介绍: Progress in Neurology and Psychiatry is published nine times a year, and is a journal for specialists in secondary care, GPs with an interest in neurology and psychiatry, community psychiatric nurses and other specialist healthcare professionals. Articles cover management, news updates and opinion in all areas of neurology and psychiatry.
期刊最新文献
Delusion of death in a patient with dementia: a case report Impact of ACP referrals forum on elderly mental health bed pressures New mania post acoustic neuroma resection: more than a coincidence Cerebellar syndrome: cause cured, but symptoms persist Using pharmacogenetic analysis in clinical management with clozapine
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1